This Phase II pilot umbrella study will match tumours in recurrent lower grade glioma patients on a molecular level with the best treatments. We will assist in accessing these drugs, including creating trials of new treatments. Lastly, we will collect an invaluable set of tissue and blood before and after treatment for future research into better treatments.
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: lumos.study@sydney.edu.au
Single molecularly-guided arm: Patients undergo molecular profiling of contemporaneous tumour tissue. If an actionable mutation is identified, a Molecular Tumour Advisory Panel recommends a matched targeted therapy. In this pilot, two participants received targeted therapies through compassionate access.
Comparator arm: Patients without actionable targets—or when matched drugs were inaccessible—received standard-of-care chemotherapy, determined with their treating clinician
LUMOS – Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study.
Kong B, Sim H, Nowak AK, et al.,
https://doi.org/10.1136/bmjopen-2021-054075
INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY,
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Pages vi106–vi107.
Benjamin Kong, Hao-Wen Sim, Benhur Amanuel, Bryan Day, Michael Buckland, Roel Verhaak, Sonia Yip, Terrance Johns, Zarnie Lwin, Mark Rosenthal, Anna K Nowak, Elizabeth H Barnes, Andrew M Scott, Jonathon Parkinson, Rosalind Jeffree, Richard De Abreu Lourenco, Peter Lau, James Whittle, Elizabeth Hovey, Lawrence Cher, Ganessan Kichendasse, Merryn Hall, Cleo Robinson, Marc Thomas, Tindaro Giardina, Emily Tu, Mustafa Khasraw, Eng-Siew Koh, Hui Gan,
https://doi.org/10.1093/neuonc/noab196.420
5 Participating Sites
10 Recruitment Target
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
